• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Dyson Steven Lewis

    9/2/25 6:55:11 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ZYXI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Dyson Steven Lewis

    (Last) (First) (Middle)
    9655 MAROON CIRCLE

    (Street)
    ENGLEWOOD CO 80112

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/18/2025
    3. Issuer Name and Ticker or Trading Symbol
    ZYNEX INC [ ZYXI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Steven Lewis Dyson 09/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ZYXI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZYXI

    DatePrice TargetRatingAnalyst
    8/1/2025$3.70Neutral → Buy
    Ladenburg Thalmann
    8/1/2025Buy → Neutral
    H.C. Wainwright
    3/12/2025$11.00 → $5.50Outperform → Sector Perform
    RBC Capital Mkts
    3/12/2025Buy → Neutral
    Ladenburg Thalmann
    10/16/2023$13.00Outperform
    RBC Capital Mkts
    1/6/2023$10.00 → $18.00Neutral → Overweight
    Piper Sandler
    2/28/2022$15.50 → $10.00Buy
    B. Riley Securities
    2/25/2022$22.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ZYXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Zynex upgraded by Ladenburg Thalmann with a new price target

    Ladenburg Thalmann upgraded Zynex from Neutral to Buy and set a new price target of $3.70

    8/1/25 8:25:35 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Zynex from Buy to Neutral

    8/1/25 8:12:40 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously

    3/12/25 7:36:55 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    SEC Filings

    View All

    SEC Form NT 10-Q filed by Zynex Inc.

    NT 10-Q - ZYNEX INC (0000846475) (Filer)

    11/12/25 5:01:51 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Inc. filed SEC Form 8-K: Leadership Update

    8-K - ZYNEX INC (0000846475) (Filer)

    10/31/25 5:00:21 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ZYNEX INC (0000846475) (Filer)

    10/14/25 5:29:10 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Disbrow Joshua R. bought $58,233 worth of shares (7,000 units at $8.32), increasing direct ownership by 11% to 72,000 units (SEC Form 4)

    4 - ZYNEX INC (0000846475) (Issuer)

    7/30/24 6:25:26 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Sets Third Quarter 2025 Earnings Call

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call. Date: Tuesday, November 18, 2025Time: 9:00 AM Eastern Time (7:00 PM Moun

    11/14/25 8:00:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair

    ENGLEWOOD, Colo., Oct. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee. "Bret Wise is a great addition to our Board of Directors as the Chair of our Audit Committee as we continue to refocus the Zynex mission and vision around patient and customer success with a renewed comm

    10/14/25 6:07:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wise Bret W

    3 - ZYNEX INC (0000846475) (Issuer)

    10/17/25 9:46:04 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Bajaj Vikram Singh

    3 - ZYNEX INC (0000846475) (Issuer)

    9/3/25 6:19:15 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Dyson Steven Lewis

    3 - ZYNEX INC (0000846475) (Issuer)

    9/2/25 6:55:11 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Leadership Updates

    Live Leadership Updates

    View All

    Zynex Announces Strategic Initiatives: Engagement of Province, Appointment of Paul Aronzon to Board of Directors, and Formation of Special Committee

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, today announced a series of strategic initiatives aimed at positioning Zynex for long-term success. Zynex has engaged Province, LLC, an internationally recognized financial advisory firm, to assist on evaluating a range of strategic alternatives, including potential capital raising opportunities and recapitalization and restructuring strategies. In add

    11/14/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair

    ENGLEWOOD, Colo., Oct. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee. "Bret Wise is a great addition to our Board of Directors as the Chair of our Audit Committee as we continue to refocus the Zynex mission and vision around patient and customer success with a renewed comm

    10/14/25 6:07:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Announces Arrival of Steven Dyson as CEO and Appointment of New Leadership in Key Roles

    ENGLEWOOD, Colo., Aug. 18, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the arrival of newly appointed CEO, Steven Dyson, and the appointment of several new leaders at the Company.  On June 30, 2025, the Company announced the Board's appointment of Steven Dyson as the incoming CEO.  Since that time, Mr. Dyson and Thomas Sandgaard, the Chairman of the Board, have been actively working wi

    8/18/25 8:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Financials

    Live finance-specific insights

    View All

    Zynex Sets Third Quarter 2025 Earnings Call

    ENGLEWOOD, Colo., Nov. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management and rehabilitation, will hold a conference call on Tuesday, November 18, 2025 at 9:00 AM Eastern Time to discuss its financial results for the third quarter ended September 30, 2025. Financial results will be issued in a press release prior to the call. Zynex management will host the conference call. Date: Tuesday, November 18, 2025Time: 9:00 AM Eastern Time (7:00 PM Moun

    11/14/25 8:00:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Reports Second Quarter 2025 Financial Results

    ENGLEWOOD, Colo., July 31, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the second quarter ended June 30, 2025. Management Commentary  "In the second quarter of 2025, we completed two transformational events. First, we appointed Steven Dyson as our new CEO. Steven brings over 25 years of experience in the medical technology sector, primarily thro

    7/31/25 4:01:00 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Zynex Sets Second Quarter 2025 Earnings Call

    ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Thursday, July 31, 2025 at 4:15 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2025.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Thursday

    7/22/25 9:15:00 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ZYXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Zynex Inc. (Amendment)

    SC 13D/A - ZYNEX INC (0000846475) (Subject)

    5/24/23 6:26:30 AM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care